Potential Excess Mortality in BRCA1/2 Mutation Carriers beyond Breast, Ovarian, Prostate, and Pancreatic Cancers, and Melanoma by Mai, Phuong L. et al.
Potential Excess Mortality in BRCA1/2 Mutation Carriers
beyond Breast, Ovarian, Prostate, and Pancreatic
Cancers, and Melanoma
Phuong L. Mai
1.*, Nilanjan Chatterjee
2., Patricia Hartge
3, Margaret Tucker
4, Lawrence Brody
5, Jeffery P.
Struewing
5, Sholom Wacholder
2
1Clinical Genetic Branch, National Cancer Institute, Rockville, Maryland, United States of America, 2Biostatistics Branch, National Cancer Institute, Rockville, Maryland,
United States of America, 3Office of Director of the Biostatistics and Epidemiology Program, National Cancer Institute, Rockville, Maryland, United States of America,
4Genetic Epidemiology Branch of the Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, Maryland, United States of America, 5National
Human Genome Research Institute, Rockville, Maryland, United States of America
Abstract
Background: Although the increase in risk of developing breast, ovarian, and prostate cancer in BRCA1 and BRCA2 mutation
carriers has been studied extensively, its impact on mortality is not well quantified. Further, possible effect of BRCA
mutations on non-cancer mortality risk has not been examined.
Methodology/Principal Findings: Using mortality data from the relatives of 5,287 genotyped participants, of whom 120
carried a BRCA Ashkenazi Jewish founder mutation, in a community-based study of the Ashkenazi Jewish population in the
Washington D.C area, we examined the association between the three Ashkenazi BRCA founder mutations and risk of overall
and non-cancer mortality. To examine risks beyond the established effects of these mutations, we analyzed the data
excluding both deaths and follow-up times after reported diagnosis of melanoma and cancer of the breast, ovary, prostate,
and pancreas. Using an extension of the kin-cohort method that accounts for informative censoring, we estimated that, in
the absence of breast, ovarian, and pancreatic cancers, and melanoma, female carriers had a life expectancy that was 6.8
years lower (95% CI: 1.2–10.5) than non-carriers. In male mutation carriers, the reduction in life expectancy, in the absence of
prostate and pancreatic cancers and melanoma, was 3.7 (95% CI: 20.4, 6.8) years. When deaths and follow-up times after
any cancer diagnosis were excluded, the difference in life expectancy was 5.7 years for women (95% CI: 20.1, 10.4) and 3.7
years for men (95% CI: 20.4, 6.9). An overall test of association for men and women together showed a statistically
significant association between BRCA1/2 mutations and increased non-cancer mortality (p=0.024).
Conclusions/Significance: These findings suggest that there may be unknown effects of BRCA1/2 mutations on non-
neoplastic diseases that cause death at older ages.
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Introduction
Germline mutations in the BRCA1 and BRCA2 (BRCA1/2)
tumor suppressor genes are highly penetrant for increased risks of
breast and ovarian cancers [1–9]. Other cancers that have been
shown to be associated with BRCA1/2 mutations include male
breast cancer, prostate cancer, pancreatic cancer, and melanoma
[8,10–12]. A recent population-based study from Canada
suggested that BRCA1/2 mutations were associated with a
significantly increased risk of cancers overall and at sites other
than breast and ovary [12].
Although the exact role of these genes on carcinogenesis is not
fully understood, existing data suggest that they play a key role in
DNA damage repair and the maintenance of genomic stability
[13]. Very little is known about the effects of BRCA1/2 mutations
on phenotypes other than cancer. Moreover, although overall life
expectancy in BRCA1/2 mutation carriers has been estimated,
using simulation models, to be decreased [14], the actual impact of
having a BRCA1/2 mutation on life expectancy is not known. A
recent actuarial analysis in female BRCA1 and BRCA2 mutation
carriers showed that mortality risk by age 70 was greater among
BRCA1 mutation carriers than among BRCA2 mutation carriers;
and that the major contributing causes of death for both BRCA1
and BRCA2 mutation carriers were breast cancer and ovarian
cancer [15]. There has been no report to date on non-cancer
mortality among BRCA1/2 mutation carriers.
To examine the effect of BRCA1/2 mutations on mortality apart
from their known effects on cancer risk, we studied the association
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cohort of first-degree relatives (FDR) of known BRCA1/2 mutation
carriers and non-carriers. We were able to use a kin-cohort
analysis that accounts for informative censoring to estimate the
effect of BRCA1/2 mutations on mortality with the effect of
mortality directly related to cancer removed [16].
Methods
Ethics Statement
This study was conducted according to the principles ex-
pressed in the Declaration of Helsinki. Use of human subject
data in this study was approved by the Special Study Institu-
tional Review Board and Clinical Center Institutional Re-
view Board of the National Cancer Institute, in accordance with
an assurance filed with and approved by the Department of
Health and Human Services. All patients provided written
informed consent for the collection of samples and subsequent
analysis.
We used data available from the cohort of FDR of participants
in the Washington Ashkenazi Study (WAS) [6] to study the
association between BRCA1/2 mutations and mortality risk at
different ages for both men and women. Details of subject
recruitment methods, data collection and laboratory testing for the
WAS have been reported elsewhere [6]. In brief, Ashkenazi Jewish
men and women living in the Washington D.C area were recruited
through public media such as posters, newspaper, and radio
announcements. A total of 5,318 volunteers were enrolled over a
nine-week period in 1996. All participants provided blood samples
after giving written informed consent. Genotyping for the three
specific Ashkenazi founder mutations in this population, 5382insC
and 185delAG in BRCA1 and 6174delT in BRCA2, was performed
with PCR-based assays for all individuals enrolled in the WAS.
Through a self-administered questionnaire, the participants also
provided detailed information regarding their family history of
cancer, including age at diagnosis, vital status information, year of
birth and year of death, for all FDR. Thirty one participants who
did not contribute any relative with known vital status were
excluded from this report. Cause of death was not ascertained and
could not be retrieved because the data were anonymized. First-
degree relatives were categorized into parents, siblings, and
children. For families in which two or more family members
participated in the study, only one member was selected in the
determination of carrier status for FDR; thus no relative was
included more than once. If volunteers from the same family
included a mutation carrier and a non-carrier, the mutation
carrier was used as the proband.
We previously described the ‘‘kin-cohort’’ analytic approach,
demonstrating how the penetrance of a disease related to a genetic
mutation can be estimated from the disease history data of the
relatives of genotyped subjects [17]. This method relies on the
basic principle that, although the genotype of the relatives are not
known, one can use Mendelian laws to estimate the expected
proportions of carriers and non-carriers among the relatives of the
genotyped individuals; alternatively, one can think of the cohort of
relatives as having ‘‘missing’’ genotypes, whose distribution can be
inferred via Mendelian laws from participants who were
genotyped. Generally, the proportion of carriers of a rare mutation
will be much higher in close relatives of a mutation carrier than in
relatives of a mutation non-carrier. We can test the association
between mutation and disease, as well as estimate genotype-
specific absolute risk (penetrance) for the disease using the inferred
genotype distribution for all relatives. Following the same
principles as in our studies of cancer incidence [6,17] and survival
after diagnosis [18], we used mortality data from the relatives of
the WAS participants to obtain age-specific cumulative risks and
hazards (interval risk) of mortality among BRCA1/2 mutation
carriers and non-carriers.
Mortality in the absence of BRCA-related cancers
We treated a diagnosis of breast, ovarian, prostate, pancreatic
cancer, or melanoma as a censoring event to eliminate the
established effects of BRCA1/2 mutations on mortality risk. Unlike
previous applications of kin-cohort estimation [17,19–21], we
could not assume that the censoring events were independent of
the mutations under study because diagnosis of a BRCA1/2
mutation-related cancer made the unknown genotype more likely
to include a mutation. The analytic approach of Chatterjee and
Wacholder [16] accounts for possible bias due to this dependent
censoring. We estimated hazards of mortality for carriers and non-
carriers in 10-year intervals and plotted the non-parametric
estimate of the age-specific cumulative risk functions. We
estimated life expectancy by numeric integration of the survival
function, i.e. the complement of the cumulative-risk function, over
the observed range of ages at mortality in the data. We obtained
confidence intervals and standard error for parameter estimated
by bootstrap sampling (500 replicates) of the WAS families in a
way that automatically accounts for the correlation of the relatives
within a family. For a global test of the difference in mortality risk
between carriers and non-carriers, we compared their average life-
expectancies based on estimates of the age-specific risk of
mortality. Wald statistics were computed by parameter estimates
divided by their bootstrap standard errors, and the associated p-
values were reported.
Mortality in the absence of all cancer
We also estimated mortality risk in the absence of any cancer
diagnosis using the same method with follow-up censored at the
time of cancer diagnosis at any site.
To examine possible impact of birth cohort effects in our
analysis, we first performed tests for interactions in the Cox
proportional hazard regression model to detect potential differ-
ences in the mortality risk between carriers and non-carriers by
birth cohort. As no significant differences were found, we adjusted
for the effect of birth cohort assuming the effect on mortality is the
same for both carriers and non-carriers.
Results
Participants who tested positive for one of the BRCA Ashkenazi
founder mutations reported having a higher proportion of female
siblings and children than did participants who tested negative. On
average, mutation carriers and their relatives were born earlier
than non-carriers and their relatives (Table 1). Twenty-seven
percent of relatives of carriers were dead at the time of the study,
compared with 25% of relatives of non-carriers. Ten percent of
siblings of carriers were dead at the time of the study, compared
with 16% of siblings of non-carriers. On the average, siblings of
carriers were born four years later than siblings of non-carriers.
Deceased parents and siblings of carriers had younger ages at
death than parents and siblings of non-carriers.
Figure 1 shows the all-cause mortality for the cohort of female
FDR of mutation carriers and non-carriers (panel 1) and the
mortality risk in female carriers and non-carriers as estimated by
the Chatterjee-Wacholder kin-cohort estimation method [16]
(panel 2). The cumulative incidence of deaths among female
FDR of carriers was higher than that for female FDR of non-
carriers.
BRCA Mutations and Mortality
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Participants Parents of Siblings of Children of
Carriers
(N=120)
Non-
carriers
(N=5167)
p-
value
2
Carriers
(N=232)
Non-
carriers
(N=10146)
p-
value
2
Carriers
(N=178)
Non-
carriers
(N=8185)
p-
value
2
Carriers
(N=184)
Non-
carriers
(N=8599)
p-
value
2
% Male 25.83 29.86 0.34 50.00 49.96 0.99 45.51 51.25 0.13 45.11 51.05 0.11
Median year
of birth
1948 1946 0.07 1917 1914 0.10 1950 1947 0.0008 1978 1972 0.0002
% Alive 40.95 47.00 0.07 89.89 84.23 0.04 98.37 98.24 0.90
Median age
of death
1
68 73 0.0006 51 58 0.86 22 10 0.87
Median year
of death
1
1979 1978 0.93 1984 1981 0.54 1989 1981 0.17
1Among deceased relatives.
2Chi-squared test for percentages or two-sample t-test for continuous variables.
doi:10.1371/journal.pone.0004812.t001
Figure 1. Cumulative incidence of all-cause mortality. Panel 1 shows the cumulative incidence of all-cause mortality among female first-
degree relatives of participants in the Washington Ashkenazi Study. Panel 2 shows the corresponding kin-cohort estimate of cumulative mortality risk
among female carriers and non-carriers of BRCA1/2 Ashkenazi Jewish founder mutations.
doi:10.1371/journal.pone.0004812.g001
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Table 2 shows the estimated mortality after excluding deaths
and follow-up time in survivors of cancers of the breast, ovary,
pancreas, or prostate, or melanoma by the modified kin-cohort
method that accounts for dependent censoring. Mortality risk in
female mutation carriers is elevated compared with female non-
carriers in a number of age groups with the increase being more
than twice and statistically significant at ages 71–80. The estimated
cumulative mortality up to age 80, excluding time after breast,
ovarian, pancreatic cancer and melanoma diagnosis, was 36%
(95% CI: 34, 39) for non-carriers and 71% (95% CI: 47, 90) for
carriers (Figure 2A). We further estimated that, in the absence of
these cancers, the average life expectancy was 80.8 (95% CI: 80.4,
81.3) years for non-carriers and 75.0 (95% CI: 70.5, 79.4) years for
carriers, or a difference of 6.8 (95% CI: 1.3, 10.5) years.
For men, we saw a similar but more modest effect of the
mutations on mortality with censoring at time of melanoma,
prostate, and pancreatic cancer diagnosis (Table 2 and Figure 2B).
The estimated cumulative mortality risk until age 80 in the
absence of these selected cancers was 56% (95% CI: 55, 58) for
non-carriers and 77% (95% CI: 58, 90) for carriers. Finally, we
estimated that, in the absence of melanoma and pancreatic and
prostate cancer, the average life expectancy was 74.7 years (95%
CI: 74.3, 75.1) for non-carriers and 71.0 years (95% CI: 68.1, 74.2)
for carriers, or a difference of 3.7 (95% CI: 0.4, 6.8) years.
Mortality in the absence of all cancer
Because cancers other than breast, ovary, pancreas, and
prostate, and melanoma could be related to BRCA1/2 mutations,
we also estimated risks of mortality with censoring at time of
diagnosis of any cancer (Table 3 and Figure 3). Among women,
the mortality differences seen in Table 2 for the age group 61–70
persisted but at a reduced level. The estimated average life
expectancy, in the absence of any cancers, was 5.7 years (95%
CI=20.1, 10.4) greater in female non-carrier than female carriers
(83.8 (95% CI=83.3, 84.3) vs. 78.1 (95% CI=73.5, 83.9)).
Among males, the estimated average life expectancy, in the
absence of all cancers, was 78.0 years (95% CI=77.6, 78.5) for
non-carriers and 74.3 years (95% CI=71.3, 78.1) for carriers – a
difference of 3.7 years (95% CI=20.4, 6.9). Although the
difference in life-expectancies between carriers and non-carriers
for females and males separately was only marginally significant at
the 0.05 a-level, a test of association for the difference combining
males and females based on Fisher’s sum of chi-square statistics
was significant with a p-value of 0.024.
We also estimated the overall mortality in the absence of any
cancer for BRCA1 and BRCA2 mutation carriers separately.
Among women, the difference in life expectancy between carriers
and non-carriers was 4.2 years for BRCA1 mutations and 5.5 years
for BRCA2 mutation. For men, the corresponding difference was
5.0 years for BRCA1 mutation carriers and 2.7 years for BRCA2
mutation carriers. None of these differences were statistically
significant.
Estimates from sensitivity analyses showed consistent effects,
though often without statistical significance in subgroups. When
adjusted for birth cohort, the excess in mortality due to BRCA1/2
mutations increased slightly for women. The overall pattern of
increased estimated mortality risk for carriers was observed in all
three generations, parents, siblings and children. We excluded
follow-up information referring to time before 1975 to reduce
possible bias that may arise due to deaths following unreported
cancers that occurred in the distant past; following this exclusion,
in the absence of all cancers, the mortality difference between
carriers and non-carriers increased; with an estimated gap in life-
expectancy of 10.3 years for women and 7.5 years for men.
Discussion
In this study, we observed an overall association between
BRCA1/2 mutations and reduced life expectancy after excluding
deaths following diagnosis of the cancers that have been shown to
be related to these mutations. The effects of the mutations were
mainly manifested through increased hazard of mortality between
ages 61 and 80. Further, the reduction in estimated life expectancy
persisted after excluding deaths following any cancer diagnosis.
To our knowledge, this is the first report to date addressing the
affect of BRCA mutations on non-cancer mortality risk. It is
commonly thought that overall life expectancy is reduced among
BRCA mutation carriers; however, no accurate estimates of this
reduction exist, and the contributing cause is thought to be mainly
breast and ovarian cancer [14,15]. Furthermore, BRCA-related
breast cancer have been thought to be associated with a worse
prognosis than sporadic cases; however, existing data are
inconsistent, with several studies suggest that there is no difference
in survival between patients with hereditary and patients with
sporadic breast cancer, particularly among patients treated with
chemotherapy [22–25]. BRCA-related ovarian cancer, on the
other hand, has been shown to be associated with an improved
survival compared with sporadic cases among patients of Jewish
descent [26–28]. The difference in survival after a breast or
ovarian cancer diagnosis among BRCA mutation carriers com-
Table 2. Estimated hazard of mortality due to carrying a BRCA mutation in the absence of melanoma and cancer of the breast,
ovary, pancreas, and prostate
1.
Age Female Male
Non-carriers Carriers Hazard Ratio Non-carrier Carrier Hazard Ratio
,50 .038 (.034, .042) .056 (.018, .102) 1.46 (0.50, 2.82) .066 (.061, .071) .079 (.026, .142) 1.19 (0.38, 2.20)
51–60 .038 (.033, .044) .047 (.000, .129) 1.26 (0.00, 3.42) .092 (.084, .099) .073 (.023, .152) 0.80 (0.25, 1.68)
61–70 .091 (.082, .101) .118 (.021, .284) 1.29 (0.22, 3.07) .179 (.168, .192) .312 (.166, .451) 1.74 (0.89, 2.55)
71–80 .242 (.225, .260) .630 (.334, .857) 2.60 (1.39, 3.64) .374 (.353, .396) .612 (.320, .825) 1.64 (0.85, 2.25)
81–90 .593 (.556, .629) .634 (.143, .972) 1.07 (0.25, 1.65) .704 (.668, .741) .844 (.418, .980) 1.20 (0.58, 1.42)
91–100 .880 (.816, .936) .853 (.030, .975) 0.97 (0.03, 1.08) .947 (.874, .997) .820 (.000, .100) 0.87 (0.00, 1.08)
1Follow-up time and deaths were censored at first report of melanoma or cancer of the breast, ovary, pancreas, or prostate.
doi:10.1371/journal.pone.0004812.t002
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PLoS ONE | www.plosone.org 4 March 2009 | Volume 4 | Issue 3 | e4812Figure 2. Cumulative incidence of mortality risk in the absence of established BRCA mutation-associated cancers. Estimated
cumulative risk of mortality among females in the absence of breast, ovarian, pancreatic cancer, and melanoma is shown in panel A. Panel B shows
the estimated cumulative risk of mortality among males in the absence of melanoma, prostate, and pancreatic cancer.
doi:10.1371/journal.pone.0004812.g002
Table 3. Estimated hazard of mortality due to carrying a BRCA mutation in the absence of any cancer
1.
Age Female Male
Non-carriers Carriers Hazard Ratio Non-carrier Carrier Hazard Ratio
,50 .026 (.023, .029) .038 (.007, .074) 1.47 (0.28, 2.90) .050 (.049, .055) .042 (.008, .091) 0.85 (0.16, 1.87)
51–60 .020 (.016, .024) .027 (.000, .098) 1.37 (0.00, 5.34) .064 (.056, .070) .067 (.009, .136) 1.05 (0.14, 2.22)
61–70 .059 (.052, .067) .078 (.000, .205) 1.31 (0.00, 3.45) .130 (.120, .142) .209 (.083, .379) 1.60 (0.62, 2.91)
71–80 .181 (.163, .199) .520 (.221, .802) 2.88 (1.16, 4.62) .288 (.267, .307) .540 (.245, .809) 1.88 (0.82, 2.87)
81–90 .543 (.502, .584) .675 (.139, .957) 1.24 (0.28, 1.79) .653 (.607, .689) .946 (.249, .972) 1.45 (0.39, 1.55)
91–100 .852 (.780, .928) .847 (.783, .979) 0.99 (0.91, 1.13) .972 (.833, .997) .972 (.000, .999) 1.00 (0.00, 1.01)
1Follow-up time and deaths were censored at first report of any cancer.
doi:10.1371/journal.pone.0004812.t003
BRCA Mutations and Mortality
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since a mortality difference between among mutation carriers and
non-carriers persisted after excluding major BRCA-related cancers
as well as all cancers.
BRCA1/2 genes have been shown to play major role in
maintaining genomic stability, but the exact mechanism remains
unknown [13]. Premature aging with decreased life-span has been
observed in animal studies using mice that were homozygous for a
hypomorphic mutation Brca1 allele and heterozygous for wild-type
p53 (Brca
D11/ D 11 p53
+/2) [29]; however, the mechanism by which
BRCA genes exert their affect on mortality is not known. In vivo
studies and mice model studies have suggested that BRCA1/2 is
involved in translation regulation and the Insulin-Like Growth
factor signaling axis [30,31], but whether these pathways are
directly related to premature aging is not clear.
The major strength of our study is that it is based on a large
community sample rather than on high-risk family registries or
cancer case series. The retrospectively constructed time of follow-
up for the relatives of the study participants gave us a unique
opportunity to estimate age-related mortality risks associated with
BRCA1/2 mutations.
One limitation of our study is the potential bias due to under-
reporting by WAS participants of cancer diagnoses in their
relatives. The known high risk of certain cancers among
carriers could lead to substantial overestimation of mortality risk
seemingly from other causes if cancers were under-reported in this
group. At the time this study was done, clinical testing for BRCA1/
2 was not available, and participants were not aware of their
mutation status. Thus, we would not expect differential reporting
due to genotype. However, even if the misreporting was non-
differential between mutation carriers and non-carriers, the
greater number of missed mutation-related cancers in mutation
carriers could exaggerate the effects. Nevertheless, the mortality
differences we observed for both women and men seem too great
to be explained completely by deaths following unreported
cancers. Moreover, the findings did not change significantly when
the data was limited to relatively recent deaths or stratified by
generations. This observation suggests that the apparent mortality
difference was unlikely to be entirely due to under-reporting of
cancers in relatives.
The major limitation of this report is that the WAS did not ask
participants about non-cancer causes of death in relatives.
Consequently, we cannot identify specific conditions that might
explain the observed association between the three BRCA1/2
Ashkenazi founder mutations and non-cancer mortality. We
censored follow-up duration at the time of any cancer diagnosis,
Figure 3. Estimated cumulative risk of mortality in the absence of any cancer. The figure shows the estimated cumulative risk of mortality
in the absence of any cancer among females (panel A) and males (panel B).
doi:10.1371/journal.pone.0004812.g003
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association between mutation status and mortality were not due to
any reported cancers. Previously, we showed that in this study
population, the overall mortality after breast or ovarian cancer
diagnosis was similar in relatives of carriers and non-carriers [18].
Moreover, other studies of Ashkenazim have found no difference
in overall survival between BRCA mutation carriers and non-
carriers after a diagnosis of breast cancer [24], and have suggested
a more favorable overall survival among women with BRCA-
related ovarian cancer [27].
In conclusion, we observed an excess in non-cancer mortality
associated with the founder BRCA1/2 mutations among an
Ashkenazi Jewish cohort, with a reduction in life expectancy of
approximately 4–6 years. If real, this observed excess mortality risk
in the absence of any cancer suggests that BRCA1/2 mutations
may exert biologic effects quite apart from their well-established
influence on cancer risk. Theoretically, these mutations may either
be associated with a small increase in risk of a variety of different
diseases, or they may be associated with moderate increase in risk
of a few major diseases. There are currently very little available
data on the effects of BRCA mutations on either overall or cause-
specific mortality, and there has been no study investigating the
association between BRCA1/2 mutations and non-malignant
conditions. However, before speculating on specific mechanisms
by which BRCA1/2 mutations might contribute to non-cancer
conditions, confirmatory studies are essential. Moreover, although
the findings in our study are intriguing, it is not clear whether the
same findings can be generalized to persons with BRCA1/2
mutations not studied in the current cohort, or to other, non-
Ashkenazi populations. Thus, additional studies, both among
Ashkenazim and with other unselected BRCA1/2 carrier popula-
tions, are needed to verify this finding. Identifying underlying
mechanisms for effects of BRCA1/2 on non-cancer mortality, if the
finding is confirmed, could lead to a better understanding of the
biological basis through which the BRCA1/2 genes exert their
impact on cancer risks as well as on other non-cancer conditions.
Furthermore, insights into the mechanism of action of the BRCA1/
2 genes could in turn facilitate research efforts aimed at finding
innovative preventive management options for BRCA1/2 mutation
carriers.
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